Literature DB >> 8189056

Role of IL-6 in activation of T cells for acquired cellular resistance to Listeria monocytogenes.

Z Liu1, R J Simpson, C Cheers.   

Abstract

We have previously shown that IL-6 is a major cytokine in the serum of mice infected with the intracellular bacterium Listeria monocytogenes, and that injection of rIL-6 before, but not after, infection promotes the recovery of mice from listeriosis. Here we demonstrate that IL-6 is required in the early stages of infection, in that injection of anti-IL-6 Ab 24 or 4 h before infection, but not 24 h after, led to a massive increase in bacterial numbers 4 or more days after infection. On the other hand, injection of rIL-6 before infection significantly suppressed bacterial numbers in the liver and spleen 3 to 4 days after infection and increased the production of IFN-gamma by in vitro cultured CD4+ and CD8+ T cells in response to specific Ag. rIL-6 did not protect SCID mice, which lack both T and B lymphocytes, against Listeria infection. The protective effect of rIL-6 was neutralized by the injection of Ab to IFN-gamma. We conclude that IL-6 plays an essential role in the activation of T cells to produce IFN-gamma, the cytokine that is central to acquired cellular resistance to intracellular bacteria.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8189056

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine.

Authors:  I S Leal; B Smedegârd; P Andersen; R Appelberg
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

2.  Differential induction of macrophage-derived cytokines by live and dead intracellular bacteria in vitro.

Authors:  Y Zhan; C Cheers
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

3.  The stress-induced virulence protein InlH controls interleukin-6 production during murine listeriosis.

Authors:  Nicolas Personnic; Serawit Bruck; Marie-Anne Nahori; Alejandro Toledo-Arana; Giorgos Nikitas; Marc Lecuit; Olivier Dussurget; Pascale Cossart; Hélène Bierne
Journal:  Infect Immun       Date:  2010-02-22       Impact factor: 3.441

4.  Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine.

Authors:  I S Leal; M Flórido; P Andersen; R Appelberg
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

5.  Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection.

Authors:  B M Saunders; A A Frank; I M Orme; A M Cooper
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

6.  Transforming growth factor beta is protective in host resistance against Listeria monocytogenes infection in mice.

Authors:  A Nakane; M Asano; S Sasaki; S Nishikawa; T Miura; M Kohanawa; T Minagawa
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

7.  Differential regulation of cytokine and cytokine receptor mRNA expression upon infection of bone marrow-derived macrophages with Listeria monocytogenes.

Authors:  A Demuth; W Goebel; H U Beuscher; M Kuhn
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

8.  Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection.

Authors:  Z Liu; R J Simpson; C Cheers
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

9.  Up-regulation of granulomatous inflammation in interleukin-6 knockout mice infected with Rhodococcus aurantiacus.

Authors:  Masashi Kohanawa; Tomonori Minagawa
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

10.  Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia.

Authors:  S A Dalrymple; L A Lucian; R Slattery; T McNeil; D M Aud; S Fuchino; F Lee; R Murray
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.